Aims: Intravenous iron therapy can improve symptoms in patients with heart failure, anaemia and iron deficiency. The mechanisms underlying such an improvement might involve chemoreflex sensing and nocturnal breathing patterns. Methods and results: Patients with heart failure, reduced left ventricular ejection fraction, anaemia (haemoglobin <13 g/dl in men; <12 g/dl in women) and iron deficiency (ferritin <100 or 100-299 mu g/L with transferrin saturation <20%) were 2:1 randomized to patient-tailored intravenous ferric carboxymaltose dose or placebo. Chemoreflex sensitivity cardiorespiratory sleep study, symptom assessment and cardiopulmonary exercise test were performed before and 2 weeks after the last treatment dose. Fifty-eight patients (38 active arm/20 placebo arm) completed the study. Intravenous iron was associated with less severe symptoms, higher haemoglobin (12.5 +/- 1.4 vs. 11.7 +/- 1.0 mg/dl, p < 0.05) and improved haematinic parameters. Ferric carboxymaltose improved the central hypercapnic ventilatory response (-25.8%, p < 0.05 vs. placebo), without changes in peripheral chemosensitivity. In particular, the central hypercapnic ventilatory responses passed from 4.6 +/- 6.5 to 2.9 +/- 2.9 L/min/mmHg after ferric carboxymaltose and from 4.4 +/- 4.6 to 4.6 +/- 3.9 L/min/mmHg after placebo (p(treatment*condition) = 0.046). In patients presenting with sleep-related breathing disorder, apnoea-hypopnoea index was reduced with active treatment as compared to placebo (12 +/- 11 vs. 19 +/- 13 events/h, p < 0.05). After ferric carboxymaltose, but not after placebo, both peak oxygen uptake (VO2) increased (Delta 1.1 +/- 2.0 ml/kg/min, p < 0.05) and VO2/workload slope was steeper (Delta 0.67 +/- 1.7 L/min/W, p < 0.01). Conclusions: Intravenous ferric carboxymaltose improves the hypercapnic ventilatory response and sleep-related breathing disorders in patients with heart failure, anaemia and iron deficiency. These newly described findings, along with improved oxygen delivery to exercising muscles, likely contribute to the favourable effects of ferric carboxymaltose in anaemic patients with heart failure.

(2022). Intravenous iron therapy improves the hypercapnic ventilatory response and sleep disordered breathing in chronic heart failure [journal article - articolo]. In EUROPEAN JOURNAL OF HEART FAILURE. Retrieved from https://hdl.handle.net/10446/234550

Intravenous iron therapy improves the hypercapnic ventilatory response and sleep disordered breathing in chronic heart failure

Caravita, Sergio;Pelucchi, Sara;
2022-01-01

Abstract

Aims: Intravenous iron therapy can improve symptoms in patients with heart failure, anaemia and iron deficiency. The mechanisms underlying such an improvement might involve chemoreflex sensing and nocturnal breathing patterns. Methods and results: Patients with heart failure, reduced left ventricular ejection fraction, anaemia (haemoglobin <13 g/dl in men; <12 g/dl in women) and iron deficiency (ferritin <100 or 100-299 mu g/L with transferrin saturation <20%) were 2:1 randomized to patient-tailored intravenous ferric carboxymaltose dose or placebo. Chemoreflex sensitivity cardiorespiratory sleep study, symptom assessment and cardiopulmonary exercise test were performed before and 2 weeks after the last treatment dose. Fifty-eight patients (38 active arm/20 placebo arm) completed the study. Intravenous iron was associated with less severe symptoms, higher haemoglobin (12.5 +/- 1.4 vs. 11.7 +/- 1.0 mg/dl, p < 0.05) and improved haematinic parameters. Ferric carboxymaltose improved the central hypercapnic ventilatory response (-25.8%, p < 0.05 vs. placebo), without changes in peripheral chemosensitivity. In particular, the central hypercapnic ventilatory responses passed from 4.6 +/- 6.5 to 2.9 +/- 2.9 L/min/mmHg after ferric carboxymaltose and from 4.4 +/- 4.6 to 4.6 +/- 3.9 L/min/mmHg after placebo (p(treatment*condition) = 0.046). In patients presenting with sleep-related breathing disorder, apnoea-hypopnoea index was reduced with active treatment as compared to placebo (12 +/- 11 vs. 19 +/- 13 events/h, p < 0.05). After ferric carboxymaltose, but not after placebo, both peak oxygen uptake (VO2) increased (Delta 1.1 +/- 2.0 ml/kg/min, p < 0.05) and VO2/workload slope was steeper (Delta 0.67 +/- 1.7 L/min/W, p < 0.01). Conclusions: Intravenous ferric carboxymaltose improves the hypercapnic ventilatory response and sleep-related breathing disorders in patients with heart failure, anaemia and iron deficiency. These newly described findings, along with improved oxygen delivery to exercising muscles, likely contribute to the favourable effects of ferric carboxymaltose in anaemic patients with heart failure.
articolo
2022
Caravita, Sergio; Faini, Andrea; Vignati, Carlo; Pelucchi, Sara; Salvioni, Elisabetta; Cattadori, Gaia; Baratto, Claudia; Torlasco, Camilla; Contini, Mauro; Villani, Alessandra; Malfatto, Gabriella; Perger, Elisa; Lombardi, Carolina; Piperno, Alberto; Agostoni, Piergiuseppe; Parati, Gianfranco
(2022). Intravenous iron therapy improves the hypercapnic ventilatory response and sleep disordered breathing in chronic heart failure [journal article - articolo]. In EUROPEAN JOURNAL OF HEART FAILURE. Retrieved from https://hdl.handle.net/10446/234550
File allegato/i alla scheda:
File Dimensione del file Formato  
European J of Heart Fail - 2022 - Caravita - Intravenous iron therapy improves the hypercapnic ventilatory response and.pdf

accesso aperto

Versione: publisher's version - versione editoriale
Licenza: Creative commons
Dimensione del file 576.66 kB
Formato Adobe PDF
576.66 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Aisberg ©2008 Servizi bibliotecari, Università degli studi di Bergamo | Terms of use/Condizioni di utilizzo

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10446/234550
Citazioni
  • Scopus 10
  • ???jsp.display-item.citation.isi??? 9
social impact